Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
Institute of Hematology and Medical Oncology L. and A. Seràgnoli, S. Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy. pierpaolo.piccaluga@unibo.it
Pier Paolo
PP
Piccaluga
Michele
M
Malagola
Michela
M
Rondoni
Mario
M
Arpinati
Stefania
S
Paolini
Anna
A
Candoni
Renato
R
Fanin
Emanuela
E
Messa
Maria Teresa
MT
Pirrotta
Francesco
F
Lauria
Giuseppe
G
Visani
Daniele
D
Alberti
Francesca
F
Rancati
Vincenza
V
Vinaccia
Domenico
D
Russo
Giuseppe
G
Saglio
Michele
M
Baccarani
Giovanni
G
Martinelli
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007558:Italy; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D019009:Proto-Oncogene Proteins c-kit; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit